“Intriguing And Fishy,” Says Top Indian Committee On HPV Vaccine Trials; Lashes Out At PATH, Local Regulators For Violations
This article was originally published in PharmAsia News
A powerful parliamentary committee thrashed top Indian regulators for gross violations and failure to perform mandated roles in overseeing clinical trials of GSK and Merck HPV vaccines. The committee now seeks to widen the scope of its investigations and alert the WHO, UNICEF and the governments of Uganda, Peru and Vietnam, where similar trials may have been allowed.
You may also be interested in...
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.